ClinicalTrials.gg
RecruitingNCT06286150Updated Feb 29, 2024

Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery

An interventional study of Surgical robot system in Lung Cancer, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-29.

Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Sep 2023, registered Feb 2024).
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University — 20 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · The First Affiliated Hospital of Guangzhou Medical University.

Planned enrollment
17th of 18
20 · median 110
Started
2023
with 3 others
No phase
12 of 26
9 open now
Primary completion
2025-07
later than 2 of 19 live
Registered
6th of 26
by date

Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, this one is the 17th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2023, is one of 12 with no phase, reaches primary completion later than 2 of the 19 other live ones, and was the 6th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

20 of the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, or all of them as a file.
02

Study summary

Robotic surgical systems have become a promising surgical assistance system, with unique advantages such as 3D high-definition visual system, highly flexible wrist-jointed instruments, and automatic fitering of hand tremors. Robotic surgical systems is applied in various fields including urology, general surgery, cardiothoracic surgery, head and neck surgery, and gynecology. Currently, the Da Vinci surgical robot system is the most widely used robot system globally. However, the Da Vinci robot system for single-port laparoscopic surgery has not yet been launched in China. Therefore, the investigators conduct a prespective, single-center study to evaluate the efficacy and safety of single-port surgical robot system in thoracic surgery.

03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • surgical robot system
  • efficacy
  • safety
  • thoracic surgery
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 75 years, regardless of gender.
  • Patients who require endoscopic surgical treatment and have indications for lung segment/lobe resection; for pre-trial subjects, there is no restriction on the type of procedure, and inclusion is based on the investigator's judgment of having indications for thoracic surgery.
  • Preoperative of I-III.
  • Voluntary participation in the clinical trial and willingness to provide informed.

consent, either by the subject or their guardian.

  • Willingness to cooperate and complete trial follow-up and related examinations.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of thoracic surgery or previous history of other malignant tumors deemed unsuitable for inclusion by the investigator.
  • Patients with severe comorbidities (cardiac, pulmonary, hepatic, cerebral, renal diseases) or physical weakness who cannot tolerate general anesthesia or surgery.
  • Patients with severe bleeding tendencies or coagulation disorders.
  • Patients in the active phase of infectious diseases or with other severe non-communicable infections.
  • Patients positive for (HIV) antibodies or syphilis seropositive patients.
  • Patients with a suspected or confirmed alcohol, drug, or substance addiction.
  • Patients with a history of epilepsy, mental illness, or cognitive impairment.
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the trial period.
  • Participation in other interventional clinical trials within 3 months prior to signing the form.
  • Other situations in which the investigator deems inappropriate for participation in this clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    single-port robot group

    Procedure: Surgical robot system

Interventions

  • ProcedureSurgical robot system

    SHURUI Single-port surgical robot system

06

What researchers measure

Primary outcomes

  1. Intraoperative conversion rate

    The conversion from a single-port laparoscopic surgery system to other surgical Instrument control systems, such as traditional thoracoscopy or open surgery.

    Time frame: Within 1 day after surgery

  2. Surgical complications rate

    The incidence rate of instrument-related or potentially instrument-related surgical complications meeting Clavien-Dindo grade 3 or above criteria from the time of incision

    Time frame: 30 days after surgery

Secondary outcomes

  1. Intraoperating bleeding volume

    The amount of intraoperative bleeding from the start to the end of the surgery in the study subjects

    Time frame: Within 1 day after surgery

  2. Surgical time

    Time frame: Within 1 day after surgery

  3. Length of hospital admissions

    The total number of days of hospitalization from the day of surgery to discharge for the study subjects. If a subject is admitted in the afternoon or discharged in the morning, the day of admission or discharge is recorded as 0.5 days.

    Time frame: Within 30 day after surgery

  4. Postoperative wound pain score

    Assessment will be conducted using the Numerical Rating Scale (NRS)

    Time frame: 1, 24 and 72 hours after surgery

  5. Surgeon satisfaction

    The surgeon satisfaction survey questionnaire consists of two parts: performance-related (12 questions) and surgeon comfort-related ratings (8 questions). The scoring criteria are as follows: Each question is scored on a scale of 1-5, with a maximum score of 5. The total score is out of 100

    Time frame: Within 4 hours after surgery

  6. Adverse events

    Incidence of adverse events (AE), serious adverse events (SAE), and overall surgical complication rate (evaluated using the Clavien-Dindo grading system)

    Time frame: Within 1 day after surgery

  7. Rate of re-admission to hospital

    Time frame: 30 days after discharge

  8. Rate of reoperation

    Time frame: 30 days after surgery

  9. Postoperative mortality

    Time frame: 30 days after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jul 2025, 22 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 22 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2024
First posted
Feb 29, 2024
StartActual
Sep 15, 2023
Primary completionEst.
Jul 15, 2025
CompletionEst.
Jul 15, 2027
Last update
Feb 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06286150
Responsible party
Jianxing He (Director, The First Affiliated Hospital of Guangzhou Medical University) — Principal investigator
First posted
Feb 29, 2024
Start date
Sep 15, 2023
Primary completion
Jul 15, 2025 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Feb 29, 2024

Study contacts

Jianxing He, M.D.
Contact
hejx@vip.163.com
+86-20-83337792

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion